SCHEMBL1481375

SCHEMBL1481375

COc1ccc(/C=C/c2nc(-c3ccc(Cl)cc3Cl)cn2CC(=O)Nc2ccncc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
CNR1 P21554 2/20 0.41
ALDH1A1 P00352 5/20 0.41
LMNA P02545 4/20 0.41
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
THPO P40225 1/20 0.40
NPC1 O15118 1/20 0.40
GMNN O75496 1/20 0.40
RAB9A P51151 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481379 1.00 MAPT (0.41) MAPTCNR1ALDH1A1LMNAKMT2A
SCHEMBL12829061 0.91 TP53 (0.44) MAPTLMNAKMT2AMEN1TP53
SCHEMBL1481873 0.86 TRPV1 (0.45) MAPTALDH1A1LMNA
SCHEMBL1481876 0.86 TRPV1 (0.45) MAPTALDH1A1LMNA
SCHEMBL1481478 0.85 MAPT (0.43) MAPTCNR1POLB
SCHEMBL1481479 0.85 MAPT (0.43) MAPTCNR1POLB
SCHEMBL1480965 0.84 CNR1 (0.45) MAPTCNR1ALDH1A1LMNAKMT2A
SCHEMBL1480963 0.84 CNR1 (0.45) MAPTCNR1ALDH1A1LMNAKMT2A
SCHEMBL1483019 0.83 CNR1 (0.45) MAPTCNR1ALDH1A1KMT2AMEN1
SCHEMBL1480617 0.83 CNR1 (0.49) MAPTCNR1ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885CNR1 3369/4885ALDH1A1 710/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885CNR1 3369/4885ALDH1A1 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.